Podcasts about fatty liver

Lipid storage disease characterized by the accumulation of large vacuoles of triglyceride fat in liver cells via the process of steatosis

  • 179PODCASTS
  • 565EPISODES
  • 31mAVG DURATION
  • 5WEEKLY NEW EPISODES
  • Oct 5, 2022LATEST
fatty liver

POPULARITY

20152016201720182019202020212022

Categories



Best podcasts about fatty liver

Latest podcast episodes about fatty liver

Midlife Mommas
How to Love Your Liver for Better Midlife Health

Midlife Mommas

Play Episode Play 15 sec Highlight Listen Later Oct 5, 2022 29:37


Liver health?? Sounds a bit unsavory, doesn't it? Welllll, your liver is a vital organ and it merits a conversation during midlife.What does the liver do?How can you nourish it?What harms it?How can you love it?I really hope you'll listen to this episode. Cam and Amelia try to sprinkle serious health topics amongst fun, joyful ones. This one is a "don't miss". In previous episodes we've covered alcohol & caffeine, medicines and skin care products. Do you know what ALL of these things have in common? You guessed it, they are all metabolized by your liver. Plus, we've got a give-away! See the details below!Queen of Thrones Castor Oil Special for listeners!!!Purchase Castor Oil Pack for Liver Kit + FREE Castor Oil Eye Compress Kit (Save 42.97!)Go HERE to purchase!Coupon Code: MOMMAWELLNESSOctober 5-October 8, 2022 Cam's Favorite Essential Oil Site for Products and Recipes:https://www.aromatics.com/blogs/wellness*Not an affiliate link

Surfing the Nash Tsunami
S3-E57.4 - Potential Bottlenecks in Getting Drugs to NAFLD Patients

Surfing the Nash Tsunami

Play Episode Listen Later Oct 2, 2022 12:52


After a month of major Fatty Liver medical meetings, Jörn Schattenberg, Louise Campbell and Roger Green explore emerging stories that will shape the next 6-12 months in Fatty Liver disease. This conversation speculates where potential bottlenecks in getting drugs to patients might emerge.Louise points to payers as a significant barrier en route to product adoption. Roger suggests it depends on the healthcare system, but generally agrees with Louise. He references the past development of a Hep C treatment for a comparable example. Payers slowed adoption of drugs with clear long-term benefits due to the short-term cash outlays. Jörn also shares his belief that payers will be the source of bottleneck. He suggests that appropriate patient pathways and stratification provide the best counter-strategy. In response, Louise returns to her point that our health systems are not ready to implement Fatty Liver drug therapy yet, much less over the next 6-12 months.The conversation then shifts to the more recent theme of a “combo-combo world,” coined by Mazen Noureddin in Season 3, Episode 43. Mazen had introduced the idea that combinations of biomarkers are necessary to diagnose and stage, while combinations of drugs provide optimal therapy. To finish, Jörn discusses the value of the consortia – LITMUS, NIMBLE, NAIL-NIT and Rohit Loomba's Goldmine – in moving this issue forward.

Surfing the Nash Tsunami
S3-E47.5 - Combination NIT Biomarkers and Developing a Viable System for Treating Patients

Surfing the Nash Tsunami

Play Episode Listen Later Oct 2, 2022 11:40


After a month of major Fatty Liver medical meetings, Jörn Schattenberg, Louise Campbell and Roger Green explore emerging stories that will shape the next 6-12 months in Fatty Liver disease. In this final conversation, the group discusses the importance of combination NIT biomarkers in developing a viable system for treating patients. The key is that NITs provide a viable strategy for widespread patient screening and staging, whereas biopsy does not.Roger also asks about several other issues that will come to the fore in the next year. The first item is the Nomenclature conference. Jörn describes it as a moving target with a clear split between the hemispheres. Asia is moving toward a concept more like metabolic-associated disease, however, Europe and North America are not. He notes that an ongoing process of consensus leaves him hopeful. Roger suggests that redefining the disease itself might lead regulators to disregard the vast amounts of research accomplished. Unfortunately, this has the potential to set the field back several years. Jörn agrees that it is imperative that any solutions do not push back drug or diagnostic approvals. The existing data and procedures around patient enrolment in trials remain clear.The final question returns to the issue of what changes might take place over the next year. Each answer differs and continues themes found in the earlier conversations. Surf on for the group's predictions.

Surfing the Nash Tsunami
S3-E47.1 - Collaborative energies shifting the force around Fatty Liver

Surfing the Nash Tsunami

Play Episode Listen Later Oct 1, 2022 12:10


After a month of major Fatty Liver medical meetings, Jörn Schattenberg, Louise Campbell and Roger Green explore emerging stories that will shape the next 6-12 months in Fatty Liver disease. This conversation focuses on the need for different specialties to align in treating the complete range of non-communicable metabolic diseases.Jörn starts the conversation with a personal highlight: he attended last month's EASD meeting for the first time. Historically, few hepatologists attend this meeting. He views his attendance as indicative of a trend: hepatologists and endocrinologists working together on diabetes and NAFLD. Louise echoes the sentiment that liver health is gaining traction as a critical function of holistic patient management. However, she notes cardiology appears to be slow on the uptake. She also asserts that nurses should have a clear role in this discussion around holistic patient management.Roger links collaborative energy to a completely different kind of energy formation: capital investment. He notes Akero's recent filing for $230 million in equity to help bring efruifermin to market based on Phase 2b results. If this effort succeeds, it may signify that the financial markets are becoming more optimistic about NASH drugs after several years of extreme skepticism.As the conversation winds down, Jörn returns to his original theme to discuss how endocrinologists have received the concept of liver disease as part of multimorbidity management in patients living with T2DM. He reports that the endocrinologists have been eager to learn the liver testing tools and metrics they should use. They require simple tests with high negative predictive values. That way, they know when it is time to send a patient to the hepatologist. This reminds Roger of Quentin Anstee's talk in Dublin about the different roles that first and second biomarker tests play in the diagnostic process. The conversation finishes with Roger making a correlation between Quentin's talk and Jörn's recent experiences engaging with the endocrinology community.

Surfing the Nash Tsunami
S3-E47.2 - The role of multiple biomarker tests in the diagnostic process

Surfing the Nash Tsunami

Play Episode Listen Later Oct 1, 2022 12:49


After a month of major Fatty Liver medical meetings, Jörn Schattenberg, Louise Campbell and Roger Green explore emerging stories that will shape the next 6-12 months in Fatty Liver disease. This conversation explores the role of multiple biomarker tests in the diagnostic process and how these might vary in the panelists' home countries.To begin, Louise notes that in the UK, many primary care physicians do not perform even basic liver tests, making it impossible to compute FIB-4. Roger questions whether publicizing of guidelines like the AACE or EASL guidelines will speed uptake of FIB-4. The guidelines recommend that front-line physicians not screen their T2DM patients for NAFLD, since 80+% will test positive. Instead, they recommend using a FIB-4 test to identify patients at risk due to current fibrosis. Roger then asks whether these guidelines will move into actual practice. Louise and Jörn each note that in their countries, front-line professionals are not required to perform liver enzyme blood work. Yet, these tests are pivotal for early liver screening. Louise doubts that change will come until after an expensive drug is approved, at which point there will be economic motivation to test. Jörn is more hopeful that with simple tests, he and other hepatologists can educate endocrinologist colleagues on the reasons to adopt this testing strategy over time.As the conversation wraps up, Jörn begins to segue from the future of care pathways to the exciting future of drug development.

Surfing the Nash Tsunami
S3-E47.3 - Implications of Positive Drug Trials and Eventual Approvals on NAFLD Treatment

Surfing the Nash Tsunami

Play Episode Listen Later Oct 1, 2022 12:15


After a month of major Fatty Liver medical meetings, Jörn Schattenberg, Louise Campbell and Roger Green explore emerging stories that will shape the next 6-12 months in Fatty Liver disease. This conversation focuses on exciting data they anticipate for multiple different drugs. They also discuss the implications positive drug trials and anticipated approvals will have for NAFLD treatment.Roger starts by discussing the educational work Intercept was beginning before obeticholic acid received its complete response letter in 2020. He underlines the logic that doctors will be more eager to learn how to treat when given a reliable way to achieve results.Jörn expresses specific enthusiasm about the future of FGF-21s as implicated by the recent Akero Phase 2b results. Roger then notes the promising data and/or approvals on the horizon for four different modes of action. He suggests that with these, the ideas of combination therapy and disease regression or resolution may become real for the first time. Louise agrees about the promise of the medications. However, she expresses strong concern that the diagnostic and patient management structures will not be in place before the drugs arrive. This shortcoming will slow the ability to bring these benefits to patients. Jörn returns to the excitement about the drugs and the idea that significant amounts of data may come as soon as November's AASLD meeting. As the conversation ends, the group begins to explore where bottlenecks in getting drugs to patients might exist.

Surfing the Nash Tsunami
S3-E47 - What does the next year hold for the NAFLD-metabolic disease link?

Surfing the Nash Tsunami

Play Episode Listen Later Sep 29, 2022 57:28


The last month has witnessed several major Fatty Liver conferences and others that touch on NAFLD in the context of metabolic disease. One common theme has been the need for different specialties to align in treating the complete range of non-communicable metabolic diseases. In this episode, Roger Green, Jörn Schattenberg and Louise Campbell propose factors that have the potential to dramatically shift the force around fatty liver disease over the next six months.Jörn starts the conversation with a personal example of a larger trend: he attended last month's EASD meeting for the first time. Historically, few hepatologists attend this meeting, but Jörn believes his attendance is indicative of a trend: hepatologists and endocrinologists working together on diabetes and NAFLD. Louise echoes the sentiment that liver health is gaining traction as a critical function of holistic patient management, although cardiology appears to be slow on the uptake.Roger links this collaborative energy to a completely different kind of energy formation: capital investment. He notes Akero's recent filing for $230 million in equity to help bring efruifermin to market based on Phase 2b results. If this effort succeeds, Roger suggests that it may signify that the financial markets are becoming more optimistic about NASH drugs after several years of extreme skepticism.Next, Jörn returns to his original theme to discuss how endocrinologists have received the concept of liver disease as part of multimorbidity management in patients living with T2DM. He reports that endocrinologists have been enthusiastic about the idea and eager to learn the liver testing tools and metrics they should use.The group then responds to the AACE guidelines promoted last May. The guidelines recommend that front-line physicians not screen their T2DM patients for NAFLD, since 80+% will test positive. Instead, guidelines recommend using a FIB-4 test to identify patients at risk due to current fibrosis. Roger asks whether these will move into actual practice. Louise and Jörn each state that in their countries, front-line treaters are not required to perform liver enzyme blood work. These tests are pivotal for early liver screening. Louise doubts that change will come until after an expensive drug is approved, at which point there will be economic motivation to test. Jörn is more hopeful that with simple tests, he and other hepatologists can educate endocrinologist colleagues on the reasons to adopt this testing strategy over time.The conversation shifts to speculation as to whether prescribers or payers will be the source of bottleneck in patient care pathways at the outset of a drug approval. The group generally agrees that pushback will come from the payers and that healthcare systems are not yet ready. They then look towards the social and political will to take action on the crisis. In response to Roger's question, the group acknowledges the immense hurdles present in changing provider behavior over the next 6-12 months while stressing the importance of provider education and patient empowerment.Finally, the group discusses the future of the recently coined “combo-combo world,” where correct diagnosis will require a combination of biomarker tests and treatment may require a combination of therapies. At the end, Roger asks what changes each member envisions. Surf on to find out.

The Doctor Is In Podcast
928. Fructose Fatty Liver

The Doctor Is In Podcast

Play Episode Listen Later Sep 27, 2022 27:35


Back in the 70's, there was only one type of major liver problem and that was cirrhosis of the liver caused by alcohol. Today, you may have heard of non-alcoholic fatty liver, or NAFL for short. It's a very dangerous condition that Dr. Martin thinks needs a new name. Fructose fatty liver is better because it describes the cause of the condition… fructose! Join Dr. Martin as he teaches on fructose fatty liver and why it's so dangerous to your health. If you have fructose fatty liver, you have problems. Dr. Martin shares ways to correct the condition in today's episode.  

biobalancehealth's podcast
Healthcast 614 - Metformin® is a Miracle Drug for Aging and Obese Patients

biobalancehealth's podcast

Play Episode Listen Later Sep 22, 2022 24:48


See all the Healthcasts at https://www.biobalancehealth.com/healthcast-blog/ One of my patients asked me why I was putting her on Metformin if she wasn't really diabetic yet, another woman I was consulting on asked why I'd put her on a dangerous drug, and another patient with Fatty Liver refused to take Metformin because it is for Diabetes and not for Fatty Liver!  These patients made it clear that I had to create a Healthcast and blog about the miracle drug, Metformin.   Metformin has been around since 1994 while early in my private practice. Metformin quickly became the first line therapy for type 2 diabetics.  was the first line of treatment for type 2 diabetics.  In that 40 years using Metformin for diabetes has opened a whole range of other diseases and conditions that Metformin can be used for, such as:   Reducing risk of Cancer recurrence, all cancers Weight loss Lowering triglycerides Treating insulin resistance Treating Prediabetes Mood Disorders, Psychiatric problems Decreases NAFL from becoming Liver cancer Polycystic ovarian Disease Infertility Aging and the symptoms of aging People on Metformin have a lower rate of mortality     How does Metformin work? Metformin exerts its hypoglycemic effects by: decreasing glucose production from the liver increasing insulin receptors' sensitivity in various body tissues increasing secretion of growth differentiating factor, which reduces appetite and calorie intake. When I find a patient with signs of Diabetes, a high HBA1C, and or an elevated fasting Insulin level (above 10), or consistently elevated FBS I prescribe Metformin for patients who don't have AODM yet, but who will progress to it if they are not treated and learn to eat low glycemic foods, and to exercise.  Generally, the patients that I label with Metabolic Syndrome, revert to normal and don't proceed to AODM. I also use this drug for weight loss because most weight gain in women after 40 is because they have become menopausal and have a loss of testosterone which causes them to gain weight and become insulin resistant.   Metformin, Diet and Exercise all work together to reverse the process and decrease a woman's chance of getting AODM.  What medical Diseases and Problems Do I use Metformin for? Other patients who may or may not have IR, but who have elevated liver enzymes from Non-Alcoholic Fatty Liver Disease (NAFL) are placed on Metformin to reverse this problem as well.  I have seen many patients who thought they were doomed to having fatty liver and possibly developing Liver Cancer, become healthy, lose weight and normalize their previous Fatty Liver. High Triglycerides (TGs) are generally from too many simple carbs over time and increase as insulin resistance gets worse with aging and length of time eating the wrong diet.  Diet and exercise are necessary to drive the TG down to normal, but patients rarely stick to these lifestyle measures unless they see a visible change in their body composition.  Metformin can make that possible and be the factor that leads patients to a healthier lifestyle. “Cancer Loves Sugar” so I try to explain that the 2 largest factors in recurrence of a cancer or even getting any cancer are obesity and dysregulation of blood sugar with insulin resistance. Both can be transformed by diet exercise and metformin!  You can literally decrease your cancer risk by losing weight and not eating simple carbohydrates. Elevated Prolactin levels that are not in the tumor range are lowered in both men and women with Metformin. The article in the latest Psychiatry Today shows a use for Metformin for mood disorders. Psychiatrists use metformin ER to decrease the weight gain often caused by anti-psychotics.  They also find that metformin increases repair in the brain and activates the brain to increase Motivation, cognition, and dopamine. This is a benefit for patients who may be on antipsychotics for life and need help with the side effects. Countering Inflammation that causes osteoporosis, degenerative brain diseases, frailty and arthritis.     Antiaging is stimulated by Metformin..how does it work? Improving nutrient sensing Enhancing autophagy Enhancing intracellular communications Protecting against macromolecular damage Delaying stem cell aging Modulating mitochondrial function Regulating gene transcription Lowering telomere attrition   How Do I prescribe Metformin? There are two types of Metformin, the short acting form of metformin which is made to be taken with each meal to manage BS after eating for diabetics only, and the long-acting type of Metformin, which is called Metformin ER or XR, and this is the type I use for every other problem including IR, and Prediabetes.  The long-acting form must be taken with a meal, or it simply will not work!  Generally, the dose is started with on 500 XR tablet with the largest meal of the day, then increasing each week to the max of 4 x 500XR tablets per day if needed.  I write smaller doses for less severe dysregulations, and larger for severe IR, Obesity, and higher weight individuals.  Don't take Metformin plain for the conditions above unless you have Diabetes and need help lowering your blood sugar. For patients who are on either form of Metformin for long periods of time, Methyl B12 should be prescribed as Why are we all not on this drug? The FDA works slowly and even though many of these attributes of Metformin are known in the medical community, doctors tend not to use a drug that is not approved by the FDA…even though medical studies have proved its benefit!  For those of us who know that the FDA may never look at this drug for any other uses, and that our patients need it now for reasons other than metabolic syndrome, we forge ahead and use it off label for the reasons above! Ask your doctor about this inexpensive medication that can do you so much good!

Surfing the Nash Tsunami
S3-E45.2 - Paris Review: Opening and Closing Sessions

Surfing the Nash Tsunami

Play Episode Listen Later Sep 19, 2022 15:59


The episode starts with Louise sounding an alarm about the rate of growth for cirrhosis and bridging or advanced cirrhosis. She is concerned that as more data is collected, an increasing number of lives fail to be served with the passage of time. She then mentions a talk by Oxana Drapkina from Session 1 about how the Russian system operates. On the surface, this sounds to be more efficient than Western approaches.Next, Jeff and Jörn share their thoughts and satisfaction on the closing session, in which both participated. The diversity of regional challenges and the varied positions of the panelists led to a lively and far-reaching discussion. In response to a question from Jörn, Jeff expands on what he learned while working on food policy in the Obama White House.In the final part of this episode, Roger raises a few issues of interest. He discusses the ability to educate and work more quietly in Congress than in public venues. He also mentions the value of educating physicians to think of Fatty Liver issues when treating other metabolic patients. Louise joins to consider the idea that while different specialties look down organ silos, reality often presents an integrated metabolic challenge.

The Dr. Livingood Podcast - Make Health Simple
How To Remedy A Fatty Liver In 14 Days

The Dr. Livingood Podcast - Make Health Simple

Play Episode Listen Later Sep 18, 2022 10:34


Did you know that skinny people have more fatty liver problems than overweight people? Luckily, there are natural remedies that you can get from food. In this video, I go over why you should take care of your liver, and how 1 drink can remove fat from your liver in as little as 2 weeks. Liver health isn't something that many people think of. From nights of drinking to days of overeating, our liver can get bogged down from how we treat it. Luckily, by taking one drink, you can reduce the amount of fat built up inside your liver by almost 50%. Not only will this drink help reduce the fat in your liver, but lowering your carbohydrate intake will help you lose weight. This will benefit your overall health and give you more energy throughout the day. If you want to take the next step to liver health, try my liver detox here: https://store.drlivingood.com/collections/all/products/livingood-daily-detox This episode was extracted from Dr. Livingood's YouTube channel. Click here to subscribe: https://bit.ly/3xUx8kl Or, click here to view the original video and any links referenced in this podcast: https://www.youtube.com/watch?v=PNaajrSdITg

Dr. Berg’s Healthy Keto and Intermittent Fasting Podcast
The #1 Absolute BEST Herb for Liver Disease (Fatty Liver, Hepatitis and Cirrhosis)

Dr. Berg’s Healthy Keto and Intermittent Fasting Podcast

Play Episode Listen Later Sep 12, 2022 5:52


The best herb for liver disease might be growing in your backyard! Dr. Berg's Keto and IF Lab: https://www.facebook.com/groups/drbergslab/ How to Bulletproof your Immune System FREE Course: https://bit.ly/39Ry3s2 FREE MINI-COURSE ➜ ➜ Take Dr. Berg's Free Keto Mini-Course! ADD YOUR SUCCESS STORY HERE: https://bit.ly/3z9TviS Find Your Body Type: https://www.drberg.com/body-type-quiz Talk to a Product Advisor to find the best product for you! Call 1-540-299-1557 with your questions about Dr. Berg's products. Product Advisors are available Monday through Friday 8 am - 6 pm and Saturday 9 am - 5 pm EST. At this time, we no longer offer Keto Consulting and our Product Advisors will only be advising on which product is best for you and advise on how to take them. Dr. Eric Berg DC Bio: Dr. Berg, 51 years of age is a chiropractor who specializes in weight loss through nutritional & natural methods. His private practice is located in Alexandria, Virginia. His clients include senior officials in the U.S. government & the Justice Department, ambassadors, medical doctors, high-level executives of prominent corporations, scientists, engineers, professors, and other clients from all walks of life. He is the author of The 7 Principles of Fat Burning. Dr. Berg's Website: http://bit.ly/37AV0fk Dr. Berg's Recipe Ideas: http://bit.ly/37FF6QR Dr. Berg's Reviews: http://bit.ly/3hkIvbb Dr. Berg's Shop: http://bit.ly/3mJcLxg Dr. Berg's Bio: http://bit.ly/3as2cfE Dr. Berg's Health Coach Training: http://bit.ly/3as2p2q Facebook: https://www.facebook.com/drericberg Messenger: https://www.messenger.com/t/drericberg Instagram: https://www.instagram.com/drericberg/ YouTube: http://bit.ly/37DXt8C Pinterest: https://www.pinterest.com/drericberg/

Surfing the Nash Tsunami
S3-E44.4 - Roger Green and Jeff Lazarus discuss NAFLD Nomenclature Conference and COVID-19

Surfing the Nash Tsunami

Play Episode Listen Later Sep 11, 2022 10:41


Roger Green starts this interview with Jeff Lazarus by asking what Jeff has been focusing on since the Barcelona conference in May. Jeff describes his extensive daily efforts to develop and garner support for a global consensus strategy on COVID-19, similar to his work on a global consensus statement on Fatty Liver disease. (This was the topic of Season 2, Episode 59.) Like the Fatty Liver work, his COVID-19 consensus work included representatives from over 200 countries with an array of public, academic and not-for-profit portfolios. However, he suggests that the high levels of agreement and, sometimes, virtually unanimity evident in the Fatty Liver work was impossible to match on an issue as immediate and terrifying as COVID-19.Roger then asks about the NAFLD Nomenclature Conference. Jeff describes the conference as a midway point for a Delphi process to explore the prospect of assigning a new name(s) in the description of fatty liver diseases. Jeff describes the six principles any name change must achieve:AffirmativeAccurate Adaptable Adoptable Applicable Able.The rest of this conversation covers prospects for success of the Nomenclature effort and the nature of the challenges ahead.

WeCare - The Health@Home Podcast
ဆီးချိုသွေးချိုရောဂါနှင့်အသည်းအဆီဖုံးခြင်း(Diabetes and fatty liver)

WeCare - The Health@Home Podcast

Play Episode Listen Later Sep 6, 2022 2:25


ဆီးချိုသွေးချိုရောဂါရှိတဲ့သူတိုင်း အဝလွန်သူတိုင်းတွင် အသည်းအဆီဖုံးခြင်းရောဂါရှိ၊မရှိကို ရှာဖွေကြည့်သင့်သကဲ့သို့ ထိရောက်မှန်ကန်သော ကုထုံးများကိုလည်းခံယူသင့်ပါတယ်။အသည်းအဆီဖုံးရောဂါကို မည်သို့ကုသနိုင်ပါသလဲ                   အရေးကြီးဆုံးက တတ်ကျွမ်းနားလည်သော ဆရာဝန်များနှင့်ပြသပြီး စစ်ဆေးမှုပြုလုပ်ကာ ကုသမှုခံယူသင့်ပါတယ်။  တိကျစွာသုတေသနပြုကာ အာနိသင်အားစမ်းသပ်ခြင်းမရှိသော သစ်ရွက်သစ်ဖုများပြုတ်သောက်ခြင်း၊ ဆေးမြီးတိုများဖြင့် ကုသခြင်းများသည် ရေတိုကာလတွင် သက်သာတယ်လို့ထင်ရနိုင်သော်လည်းရေရှည်ကာလမှ အကျိုးအာနိသင်များကို များစွာစိုးရိမ်ဖွယ်၊ သံသယရှိဖွယ်ဖြစ်နိုင်ပါတယ်။  အသည်းအဆီဖုံးပြီး အဝလွန်နေသူများက ကိုယ်အလေးချိန်ကို လျော့ချရန်ကြိုးစားသင့်ပါတယ်။ 

GO CLEANSE HEALTH CONVERSATION Podcast
88) SUGAR AND A FATTY LIVER

GO CLEANSE HEALTH CONVERSATION Podcast

Play Episode Listen Later Aug 29, 2022 20:37


Scott and Peter tackle all your questions and go deep on the topics of sugar and a fatty liver. ORDER 800 562-8819See omnystudio.com/listener for privacy information.

The Doctor's Farmacy with Mark Hyman, M.D.
How Insulin Resistance Drives Fatty Liver, Cognitive Issues, Metabolic Syndrome, And More

The Doctor's Farmacy with Mark Hyman, M.D.

Play Episode Listen Later Aug 19, 2022 61:56 Very Popular


This episode is brought to you by Paleovalley and Athletic Greens.Food should be a tool for helping us feel our best. But most people don't realize what kind of impact many of the foods they eat are having on their blood sugar—and subsequently their entire body. The symptoms of blood sugar imbalances are everyday occurrences for most people. Feeling hungry even when you just ate, craving sweets, and dealing with acne, hormonal imbalances, and signs of aging, like wrinkles, are just a few of the many symptoms of blood sugar swings. When these continue to go unchecked, more severe dysfunctions can occur, like type 2 diabetes, infertility, fatty liver disease, and dementia. In today's episode, I talk with Dr. Ben Bikman, Dhru Purohit, and Dr. Ronesh Sinha about how common dietary patterns like eating simple carbs throughout the day create constant insulin spikes leading to insulin resistance, which in turn contributes to many diseases and aging. Dr. Ben Bikman is a renowned metabolic research scientist and a popular speaker on human metabolism and nutrition. Backed by years of research, Dr. Bikman's mission is to help the world appreciate the prevalence and relevance of insulin resistance. He is the author of the book Why We Get Sick, which offers a thought-provoking yet real solution to insulin resistance and reversing prediabetes, improving brain function, shedding fat, and preventing diabetes. Dhru Purohit is a podcast host, serial entrepreneur, and investor in the health and wellness industry. His podcast, The Dhru Purohit Podcast, is a top 50 global health podcast with over 30 million unique downloads. His interviews focus on the inner workings of the brain and the body and feature the brightest minds in wellness, medicine, and mindset.Dr. Ronesh Sinha, author of The South Asian Health Solution, is an internal medicine physician who runs a lifestyle clinic in Silicon Valley focused on reversing insulin resistance in ethnically diverse patients. He is also an expert in corporate wellness and serves as the Chief Medical Officer for the Silicon Valley Employer Forum, where he serves as a global advisor to shape health benefits for over 55 major Silicon Valley companies. This episode is brought to you by Paleovalley and Athletic Greens.Paleovalley is offering my listeners 15% off their entire first order. Just go to paleovalley.com/hyman to check out all their clean Paleo products and take advantage of this deal.AG1 contains 75 high-quality vitamins, minerals, whole-food sourced superfoods, probiotics, and adaptogens to support your entire body. Right now when you purchase AG1 from Athletic Greens, you will receive 10 FREE travel packs with your first purchase by visiting athleticgreens.com/hyman.Full-length episodes of these interviews can be found here:Dr. Ben BikmanDhru PurohitDr. Ronesh Sinha Our GDPR privacy policy was updated on August 8, 2022. Visit acast.com/privacy for more information.

PATH Positive Approaches To Health
Episode 113: Road Trip... Destination Toronto, Canada - "Frozen Fruit & British Rap, They Go Very Well Together!"

PATH Positive Approaches To Health

Play Episode Listen Later Aug 18, 2022 61:44


Toni and Jenny make a road trip once again visiting our neighbor to the north – Toronto, Canada. They were able to spend some time with pal of the PATHPod, Andy De Santis. Andy was on the Pod back in December of 2020 to talk about using humor as a means of communicating nutrition information. He is back at it again – with more humor and another cookbook! This time it is all about Fatty Liver, an interesting topic considering its novelty and the lifestyle implications. Andy does a beautiful job unpacking this disease introducing topics such as fat transport to the mitochondria, the gut-liver axis and symbiotic supplements. He lays out some easy strategies for how to fit more of the foods we need to fight this disease into our diet without feeling like it's a huge and overbearing stretch. He calls out what he terms the path of least resistance – the afternoon snack and how it can be used to our advantage. Since 1 in 4 people have non-alcoholic fatty liver disease and a large majority of people don't even know it, this is an episode everyone needs to hear! Andy can be found giving out hilarious, evidence-based nutrition advice & resources on Instagram @AndytheRD or his website. 

Dr. Berg’s Healthy Keto and Intermittent Fasting Podcast
The MOST Important Fatty Liver Detox and Cleansing Antioxidant

Dr. Berg’s Healthy Keto and Intermittent Fasting Podcast

Play Episode Listen Later Aug 16, 2022 8:21


This “superhero” antioxidant is the best way to detox your liver. Find out why! Dr. Berg's Keto and IF Lab: https://www.facebook.com/groups/drbergslab/ How to Bulletproof your Immune System FREE Course: https://bit.ly/39Ry3s2 FREE MINI-COURSE ➜ ➜ Take Dr. Berg's Free Keto Mini-Course! ADD YOUR SUCCESS STORY HERE: https://bit.ly/3z9TviS Find Your Body Type: https://www.drberg.com/body-type-quiz Talk to a Product Advisor to find the best product for you! Call 1-540-299-1557 with your questions about Dr. Berg's products. Product Advisors are available Monday through Friday 8 am - 6 pm and Saturday 9 am - 5 pm EST. At this time, we no longer offer Keto Consulting and our Product Advisors will only be advising on which product is best for you and advise on how to take them. Dr. Eric Berg DC Bio: Dr. Berg, 51 years of age is a chiropractor who specializes in weight loss through nutritional & natural methods. His private practice is located in Alexandria, Virginia. His clients include senior officials in the U.S. government & the Justice Department, ambassadors, medical doctors, high-level executives of prominent corporations, scientists, engineers, professors, and other clients from all walks of life. He is the author of The 7 Principles of Fat Burning. Dr. Berg's Website: http://bit.ly/37AV0fk Dr. Berg's Recipe Ideas: http://bit.ly/37FF6QR Dr. Berg's Reviews: http://bit.ly/3hkIvbb Dr. Berg's Shop: http://bit.ly/3mJcLxg Dr. Berg's Bio: http://bit.ly/3as2cfE Dr. Berg's Health Coach Training: http://bit.ly/3as2p2q Facebook: https://www.facebook.com/drericberg Messenger: https://www.messenger.com/t/drericberg Instagram: https://www.instagram.com/drericberg/ YouTube: http://bit.ly/37DXt8C Pinterest: https://www.pinterest.com/drericberg/

Radio Naturopath
Radio Naturopath Episode 363: Why You Should Practice Deep Breathing, What Is Fatty Liver?

Radio Naturopath

Play Episode Listen Later Aug 16, 2022 58:42


This week we started out by discussing why deep breathing is good for you. There are so many reasons, but the main ones are that you lower cortisol, which in excess is destructive to body tissues, and you increase the amout of oxygen that goes to your brain and all of your organs, causing them […]

Surfing the Nash Tsunami
S3-E40.4 - Challenges of Alcohol Screening in Fatty Liver Disease

Surfing the Nash Tsunami

Play Episode Listen Later Aug 14, 2022 13:11


As the NASH pandemic grows in the number and diversity of patient cases, one patient group receiving increased notice includes patients with "lean NASH," those with "normal" BMI levels (BMI

Dr. Berg’s Healthy Keto and Intermittent Fasting Podcast

Find out the best foods to rid fat from your liver and other practical things you can do to help reduce fat on your liver. Dr. Berg's Keto and IF Lab: https://www.facebook.com/groups/drbergslab/ How to Bulletproof your Immune System FREE Course: https://bit.ly/39Ry3s2 FREE MINI-COURSE ➜ ➜ Take Dr. Berg's Free Keto Mini-Course! ADD YOUR SUCCESS STORY HERE: https://bit.ly/3z9TviS Find Your Body Type: https://www.drberg.com/body-type-quiz Talk to a Product Advisor to find the best product for you! Call 1-540-299-1557 with your questions about Dr. Berg's products. Product Advisors are available Monday through Friday 8 am - 6 pm and Saturday 9 am - 5 pm EST. At this time, we no longer offer Keto Consulting and our Product Advisors will only be advising on which product is best for you and advise on how to take them. Dr. Eric Berg DC Bio: Dr. Berg, 51 years of age is a chiropractor who specializes in weight loss through nutritional & natural methods. His private practice is located in Alexandria, Virginia. His clients include senior officials in the U.S. government & the Justice Department, ambassadors, medical doctors, high-level executives of prominent corporations, scientists, engineers, professors, and other clients from all walks of life. He is the author of The 7 Principles of Fat Burning. Dr. Berg's Website: http://bit.ly/37AV0fk Dr. Berg's Recipe Ideas: http://bit.ly/37FF6QR Dr. Berg's Reviews: http://bit.ly/3hkIvbb Dr. Berg's Shop: http://bit.ly/3mJcLxg Dr. Berg's Bio: http://bit.ly/3as2cfE Dr. Berg's Health Coach Training: http://bit.ly/3as2p2q Facebook: https://www.facebook.com/drericberg Messenger: https://www.messenger.com/t/drericberg Instagram: https://www.instagram.com/drericberg/ YouTube: http://bit.ly/37DXt8C Pinterest: https://www.pinterest.com/drericberg/

Surfing the Nash Tsunami
S3-E40 - Best Practices in Lean NASH -- Authors Provide Back Story

Surfing the Nash Tsunami

Play Episode Listen Later Aug 11, 2022 52:56


As the NASH pandemic grows in the number and diversity of patient cases, one patient group receiving increased notice includes patients with "lean NASH," those whose BMI levels are "normal." Last month, Gastroenterology published Best Practice recommendations for diagnosing and treating lean NASH. Two of the authors, Drs. Michelle Long and Mazen Noureddin, were good enough to come on the podcast to share the thinking behind this article along with its key observations and recommendations.This conversation starts with Roger Green asking Michelle and Mazen how they came to write this piece and how the paper came together working with co-author, Dr. Joseph Lim. First, as Michelle notes, "we had to all get on the same page," on the issue of the highest BMI that would be considered lean or, more precisely, not overweight. From there, the team outlined 15 Best Practices based on clinical experience, and set out to refine these based on relevant literature and recommendations from colleagues and reviewers. The co-authors note that while little of what they learned while preparing this paper was surprising, it forced them to focus on creating a fairly simple set of stepwise goals for clinicians to follow.  Louise Campbell joins the conversation to praise the simplicity and clarity of the Best Practices chart the co-authors created. After noting that this algorithm is not very different from others,  Mazen goes on to mention "a couple of things...that we're proud of:" identification of high-risk patients based on age (over 40) or presence of Type 2 diabetes. He also notes that they provided greater clarity around more advanced non-invasive tests like ELF, MAST, FAST, MEFIB, MRI, and cT1.The conversation shifts to focus on the recommendation to retest every 6 or 12 months. Louise notes this approvingly. The group agrees that screening T2D patients annually using FIB-4 is not very different than screening annually for eye, kidney or neurological complications. Roger Green joins the conversation to suggest a 3-5 year follow-up recommendation is not patient-centric, but might calm payers concerned about skyrocketing costs of treating Fatty Liver disease. Mazen shares his expectation that yearly evaluation will be cost-effective and patient-centric. Roger shares an informal belief he has developed that whether due to later stage diagnoses or different disease pathogenesis, lean NASH patients might be more costly because patients progress to cirrhosis more quickly after the original diagnosis. Michelle tends to agree but notes that more research is needed on this.Next, the conversation shifts toward diagnostic approaches. Roger mentions the possible benefit of the "Fibrosis First" method that Ian Rowe discussed the previous week (S3, E39), particularly appropriate when primary care providers observe danger signs in lean patients. Mazen points to extremely elevated liver enzyme levels (ALT of 80 or 90). Michelle agrees, but notes that most of her lean NASH patients are diagnosed in an ED with complications of cirrhosis. The group then spends time asking what might make primary care providers comfortable testing for fibrosis, even if only to pass the patient on to the appropriate specialist.  Roger asks what different groups can learn from this paper. Michelle states that this is a clear call for more research. Mazen points to Table 2 in the paper, which lists other diseases that hepatologists should consider when evaluating these patients. He continues to state that the document is helpful for non-hepatologists and hepatologists alike. Finally, he points out that clinical trials are pivotal for these patients. The last several moments focus on how to ask patients about alcohol consumption and then the closing question. Michelle notes the importance of using lists and tables in the paper to guide the special issues in treating these patients. 

Surfing the Nash Tsunami
S3-E39.5 - From The Vault: Early, Accurate Patient Information Matters

Surfing the Nash Tsunami

Play Episode Listen Later Aug 7, 2022 28:55


This week's "Conversation from the Vault" comes from September 2021, when Anthony Villiotti of NASH kNOWledge joined Louise Campbell and Roger Green to discuss what he considered the "biggest Fatty Liver story of the summer."In his answer, Tony pointed to two studies published during the summer. The San Antonio Military Medical Center study confirmed work done a decade earlier that suggested overall NAFLD and NASH incidence in a population of asymptomatic middle-aged Texans (37% NAFLD and 14% NASH) might be far higher than the most common publicly quoted numbers (25% and 5,6%, respectively). As we wrote in our conversation synopsis at the time, "Tony and Louise Campbell agree on the importance of educating children starting in their early years of schooling. Tony also comments on his belief in grass-roots education and hopes that as the COVID-19 pandemic abates, he will have more opportunities to do so. Louise talks about the need to educate/motiave primary care practitioners and related specialists to test more frequently and learn about the role the liver plays in non-communicable metabolic diseases they treat more frequently."

Surfing the Nash Tsunami
S3-E39.4 - Patient Follow-Up Challenges in Modeling NASH Diagnostics

Surfing the Nash Tsunami

Play Episode Listen Later Aug 7, 2022 17:37


One of the most important challenges facing Fatty Liver stakeholders involves improving early diagnosis for patients with clinically relevant or advanced fibrosis (F2/3). Today, a significant percentage of patients learn they are living with cirrhosis in the Emergency Department during a decompensating event. Four in ten of these patients in the UK do not leave the hospital. Episode 39 reviewed a model that Ian Rowe and Richard Parker developed to determine the most cost-effective strategy for F2/3 diagnosis.As this conversation starts, Louise Campbell notes that John Dillon reported in Barcelona that slightly over half of patients identified as having Fatt Liver via iLFT never returned for their appointments. Ian Rowe points out that this will reduce the costs in the model due to missed diagnoses but questions whether this cost reduction is truly beneficial since missed patient visits translate into non-treatment. More important, he reminds us that iLFT is under constant improvement so that data collected earlier in its lifecycle might not accurately reflect its costs and benefits today.Upon Roger Green's invitation for other questions Louise Campbell asks whether "we" (presumably the UK NHS) should do a better job supporting positive diet and exercise activity for healthcare professionals inside the system. On a more serious note, this leads Ian and Louise to focus on the policy issues that can support patients better (particularly those in the workforce). Ian points out that alcohol is issue #1 for many of these patients. He and Louise go on to point out the importance of public policy around things like soda and sweet food advertising in shifting consumers' focus or craving for bad foods. Roger suggests that this is a two-element issue: stopping advertising for soda and sweets will reduce disease over time but we also need to treat patients who already have developed disease. As he puts it, policy can "put your foot on the hose," but even if we stop the in-flow of new Fatty Liver and metabolic patients, we still have "the patients in the hose" and they will need therapy. As a final thought before wrap-up, Ian shares his belief (which Louise also holds) that VCTE might be more effective in causing changes in patient behavior than blood tests, even if they point up the exact same patient need. The difference: feedback from VCTE comes in real-time where patients get face-to-face feedback and respond, whereas bloodwork results comeback to the patient several days later and delivered impersonally. From here, the group moves to the wrap-up question, which addresses research we should be doing and action steps/changes in behavior we should be promoting. You will have to listen for yourself to hear Surfers' answers.

Surfing the Nash Tsunami
S3-E39.2 - What An Early Decision Models Tells Us About Fibrosis & Metabolic Diseases

Surfing the Nash Tsunami

Play Episode Listen Later Aug 6, 2022 13:45


One of the most important challenges facing Fatty Liver stakeholders involves improving early diagnosis for patients with clinically relevant or advanced fibrosis (F2/3). Today, a significant percentage of patients learn they are living with cirrhosis in the Emergency Department during a decompensating event. Four in ten of these patients in the UK do not leave the hospital. Episode 39 reviewed a model that Ian Rowe and Richard Parker developed to determine the most cost-effective strategy for F2/3 diagnosis.This conversation starts with Louise Campbell agreeing with the vision that led Ian and Richard to build this model. She notes recent data she heard that 85% of all US patients with cirrhosis (and 55% in the UK) learn their diagnoses for the first time in an Emergency Department, which suggests the need to improve earlier diagnosis. She notes that some UK programs are widely cited as examples of good (or best) practice, but, more important, notes that these have been cited as examples for a long time, but also notes that other regions and hospitals have not emulated them. She goes on to ask how the efficiency and number of patients captured in the model would increase if the target expanded to include all patients with metabolic disease. Ian notes that these patients were not included in the model and also suggests that the question reflects a larger question about the goal of this kind of screening.

Surfing the Nash Tsunami
S3-E39.3 - NASH challenges: Early Diagnosis and NASH Patient Management

Surfing the Nash Tsunami

Play Episode Listen Later Aug 6, 2022 14:18


One of the most important challenges facing Fatty Liver stakeholders involves improving early diagnosis for patients with clinically relevant or advanced fibrosis (F2/3). Today, a significant percentage of patients learn they are living with cirrhosis in the Emergency Department during a decompensating event. Four in ten of these patients in the UK do not leave the hospital. Episode 39 reviewed a model that Ian Rowe and Richard Parker developed to determine the most cost-effective strategy for F2/3 diagnosis.This conversation centers around challenges related to early diagnosis and NASH Patient Management. As Roger Green notes, listeners to NASH Tsunami might recall a significant number of conversations in which patients and advocates complain about doctors telling them "not to worry" about their Fatty Livers for years until the condition progresses to cirrhosis. Louise Campbell focuses on a different challenge: that of NASH patient management when patients are dealing with other metabolic diseases that are better known or where approved treatments exist.

Surfing the Nash Tsunami
S3-E39.1 - Creating An Early Diagnosis NASH Decision Model

Surfing the Nash Tsunami

Play Episode Listen Later Aug 6, 2022 12:06


One of the most important challenges facing Fatty Liver stakeholders involves improving early diagnosis for patients with clinically relevant or advanced fibrosis (F2/3). Today, a significant percentage of patients learn they are living with cirrhosis in the Emergency Department during a decompensating event. Four in ten of these patients in the UK do not leave the hospital. Episode 39 reviewed a model that Ian Rowe and Richard Parker developed to determine the most cost-effective strategy for F2/3 diagnosis.In this conversation, Ian Rowe describes the factors that motivated him and Richard Parker to build a decision model focusing on early NASH diagnosis. He identifies three data points demonstrating how severely NASH stakeholders need a better early diagnosis paradigm and then describes the five diagnostic strategies his model will test. :the high percentage of people whose liver disease is picked up for the first time when they present in the ED with decompensating disease or hepatic encephalopathythe fact that roughly four in ten of these patients will die during treatment for this initial round of liver diseasethe inefficiencies around diagnostic current methods, whereby practitioners flag abnormal liver enzyme tests and refer to specialists, where it may take months to get a specialist appointment.He then describes the five early diagnostic strategies that will be tested and contrasted in this decision curve model.

Surfing the Nash Tsunami
S3-E39 - Reviewing a Decision Model for Early NASH Diagnosis

Surfing the Nash Tsunami

Play Episode Listen Later Aug 4, 2022 63:24


One serious challenge in the overall management of Fatty Liver disease involves creating cost-effective methods for "early" diagnosis. The term "early" is relative because, as Ian Rowe puts it, a "substantial proportion" of people admitted to hospital with various symptoms of decompensating cirrhosis or hepatic encephalopathy never received a diagnosis of advanced liver disease before they presented. Simply diagnosing these patients during advanced fibrosis (F2 or F3) can save lives, improve longevity and quality of life for these patients and save money for healthcare systems, all at the same time. Ian spends the first ten minutes of this episode describing a model he and Richard Parker developed to evaluate five diagnostic strategies:Targeted -- simple non-invasive liver screening Targeted + risk stratification -- targeted assessment plus FIB-4 or VCTE (FibroScan) for patients believed to be at high riskiLFT -- automated assessment of abnormal LFTs analyzed with other systemic measures in a medical record system "Comprehensive" -- a "kitchen sink" approach that runs iLFT analysis and conducts FIB-4 +/- VCTE on every patient"Fibrosis first" -- an approach that deploys viroserological and iron testing plus FIB-4 +/- VCTE for every patient "Fibrosis first" scored best in cost effectiveness (cost per correct diagnosis of treatable liver disease) and "decision curve analysis", which looks at true positive outcomes and false positive outcomes, correctly identifying 85% of treatable liver disease patients (vs. 90% for the comprehensive approach and less than 15% for the current targeted approach.)  Fibrosis first has the added benefit of not progressing treatment for people who may have steatosis without fibrosis. The rest of the conversation entails Ian, Louise Campbell and Roger Green sharing questions and observations. Highlights:Louise agrees that the current targeted pathway approaches do not work and  identifies lack of access to advanced testing in primary care as a central issue. She asks how many additional patients with Type 2 Diabetes, other metabolic diseases or CVD could be identified through this approach. Ian cannot answer because the question is outside the scope of the research. He points out that to assess different approaches accurately, researchers and policymakers need to settle on whether the goal is to identify steatohepatitis or something broader. Louise asks about the frequency and nature of referrals. Ian notes that one issue with iLFT is a high level of referrals for conditions that might not require treatment, the most common of which is "abnormal LFT without fibrosis."Roger notes that iLFT might help patients who complain they never heard about their NASH earlier. He also recalls Quentin Anstee and Stephen Harrison discussing recently that FIB-4 can serve as a prognostic measure not only for liver-related deaths, but also CV deaths and all-cause mortality. Louise suggests that patients will do better if they adopt a  behavior belief model instead of a sick patient approach and that the earlier in disease we intervene, the more success we will have. Roger and Ian note that Louise's focus is broader in scope than his model. Ian further notes that we do not know when non-fibrotic patients should be tested again, although he has some thoughts about this. Louise notes that one element that might make iLFT costly is that only 45% of patients picked up on iLFT are referred into the model. Ian notes that this insight might require changes in the model.As the conversation winds down, it shifts toward policy issues: should we focus testing on the workforce (Louise) and it the best point of intervention to limit advertising of unhealthy foods (Ian). 

MedEvidence! Truth Behind the Data
One in Four People Have This Disease, Could You?

MedEvidence! Truth Behind the Data

Play Episode Listen Later Aug 3, 2022 40:15


This month's MedEvidence! Radio Doctors Michael Koren, Matthew Todd Braddock, DO, Jackson Downey, Albert Lopez, DO and Kevin Geddings discuss NASH, Fatty Liver and Fibroscans.  This month's MedEvidence! Radio will answer:What is NASH?What are the stages of NASH?How do you treat NASH?Is NASH reversible?Is NASH related to cholesterol problems?MedEvidence! Radio is a monthly live broadcast from WSOS 103.9 FM / 1170 AM with Kevin Geddings from St. Augustine, Florida. Dr. Michael Koren is a practicing cardiologist and CEO at ENCORE Research Group. He has been the principal investigator of 2000+ clinical trials while being published in the most prestigious medical journals.  Dr. Koren received his medical degree cum laude at Harvard Medical School and completed his residency in internal medicine with a fellowship in cardiology at New York Hospital/Memorial Sloan-Kettering Cancer Center/Cornell Medical Center.  On a personal note, Dr. Koren has a life-long interest in history, technology, Public Health, and music. He has written two musical plays.Further your learning:Participate in Clinical Research Rate, Review, and Subscribe to the MedEvidence podcast to be notified when new episodes are released.Follow MedEvidence! on Social Media to discover the Truth Behind the Data.FacebookInstagramTwitterLinkedInPowered by ENCORE Research Group at www.ENCOREDOCS.comOriginal Air Date: June 22, 2022

How To Not Get Sick And Die
Is Food Superior To Medicine for Autoimmune Disease with Rachel Favilla | EP 192

How To Not Get Sick And Die

Play Episode Listen Later Aug 2, 2022 52:32


Science continues to roll on forward proficing more and more amazing evidence of the power of food. In fact loads of the research is already there and available, it just wasn't published by the handful of gurus at the front of the line or it doesn't favour some big corporate entity and thus it disappears onto the massive pile of research that was done, never to be spoken about again. Today though we talk with a nutritionist who has her own story of solving her own chronic health issues with food.In Today's Conversation we Discuss:How you can shift your body from drug dependency to thriving with foodVeganism nutritional deficiencies and organ meatsHow plant based messaging is misleading consumers***Apply for the Emotional Eating and Weight Loss Program here: [LINK COMING SOON]***SOCIAL MEDIA--RACHEL FAVILLAWebsite: www.realsoupfortherealsoul.comInstagramFacebook--MATTY LANSDOWNJoin the Busy Mum's Facebook Group: https://mattylansdown.com/BusyMothersFBgroupInstagram: [deplatformed]... instead, join our Uncensored email list here--Intro/Outro track Tropic Love by "Diviners feat. Contacreast"

Expert Insights
NAFLD (Fatty Liver & Fibroscan)

Expert Insights

Play Episode Listen Later Aug 1, 2022


Sharlina Dhom PA and Amber Jackson APRN discuss NAFLD (Fatty Liver & Fibroscan) They highlight diagnostic testing including open access Fibroscan and they outline treatment options and process for PCP to manage or refer to GI

Surfing the Nash Tsunami
S3-E38.5 - From the Vault: NAIL-NIT tackles NAS Score Challenges

Surfing the Nash Tsunami

Play Episode Listen Later Jul 30, 2022 16:01


Our week of "Greatest Hits" episodes from the vault continues with this conversation from the episode announcing the launch of the NAIL-NIT consortium. Stephen Harrison and Mazen Noureddin discuss the thinking behind their new consortium and its targets. In this conversation, they discuss challenges with the NAS score.The early part of 2022 had several episodes discussing the increasing need to move beyond biopsy (yes, semi-quantitative, but even AI-assisted at some levels) to a future shaped by NITs. One pivotal issue that emerged regarded ballooned hepatocyte evaluation and its impact on NAS scores. As I wrote: The first section focuses mostly on what we can and cannot learn from a NAS score, and implications of its shortcomings on the drug development process. After this, Stephen Harrison notes the complex role the liver plays in energy transfer throughout the entire metabolic process. This suggests that the effects of Fatty Liver disease vary among individual patients and, as a result, drug development and patient diagnosis and treatment should provide sufficient insight to optimize each patient's therapy. As the conversation closes, Mazen Noureddin is responding to a question from Louise Campbell about what we will learn about optimal testing strategy. Mazen suggests there is unlikely to be a single "winning" test but, instead, a combination of NITs probably will be necessary to answer all the questions necessary to optimize therapy.

Surfing the Nash Tsunami
S3-E38.4 - From the Vault: NITs & Advancing NASH Therapy at AASLD 2021

Surfing the Nash Tsunami

Play Episode Listen Later Jul 30, 2022 20:42


Our week of "Greatest Hits" episodes from the vault continues with our second most popular conversation ever, which came from the wrap-up episode for AASLD2021. In this episode, Manal Abdelmalek, Jörn Schattenberg and Ian Rowe joined Stephen Harrison, Louise Campbell and Roger Green to recap NAFLD and NASH-related insights from AASLD2021 TLMdX and specifically to focus on how NITs will help, in the words of Stephen Harrison, "put a big, fat dent in Fatty Liver disease."As I wrote at the time: The conversation starts with the group congratulating Manal Abdelmalek on her wrap-up NAFLD talk at the 2021 TLMdX. From there, the group focuses on the shortcomings of using biopsy as the clinical trial gold standard and how strategic clinical trial design and interpretation of existing NIT data can build a bridge from biopsy through MRE/biopsy correlations to a total NIT future.

Unlock the Sugar Shackles Podcast
Lower Morning Glucose Levels, Reverse Fatty Liver, Insulin Resistance, & Type II Diabetes with Dr. Brian Mowll | Episode 95

Unlock the Sugar Shackles Podcast

Play Episode Listen Later Jul 27, 2022 92:26 Very Popular


BLOOD SUGAR MASTERY is back for another round this September!! BSM is my signature group coaching course that will give you all the tools to master your blood sugar so you can gain energy, sleep better, burn fat, crush cravings and feel amazing! It will help give you the clarity on what to change and why so you can ditch the confusion and start making changes that really progress you forward WITHOUT trying to change everything all at once!Enrollment opens September 7th and the next round begins September 12th! Get on the VIP waitlist here: https://www.daniellehamiltonhealth.com/blood-sugar-masteryTODAY'S GUEST: Dr. Brian Mowll is the founder and medical director of SweetLife® Diabetes Health Centers and serves clients worldwide as The Diabetes Coach™.  He is a certified diabetes care and education specialist, master licensed diabetes educator, and is certified to practice functional medicine by the Institute for Functional Medicine.For over 20 years, Dr. Mowll has been helping people around the world to optimize their health and metabolism, control blood sugar, and reverse type 2 diabetes using a natural, personalized lifestyle approach.In addition, he is the host of the #1 rated Mastering Blood Sugar podcast and author of the #1 international best-selling book, The ProFAST Diet, Burn Fat And Reverse Type 2 Diabetes In Just Six Weeks.ON TODAY'S EPISODE: Dr. Brian and I discuss...Why functional methods are so needed to help people reverse DiabetesWhat does it take to develop Type 2 Diabetes?Why Type 2 Diabetes is not just a blood sugar issueWhat happens in your body when you are insulin resistantCauses of fatty liver diseaseSymptoms of fatty liver disease and insulin resistanceWhy fasting blood sugar levels might be higher in the morning (Dawn Phenomenon)How to improve insulin sensitivity of the liverWhy counting calories is a flawed methodHow to make your body more metabolically flexibleHow the ProFast diet can help you manage your blood sugar and lose fatFOLLOW DR. BRIAN:Website: https://drmowll.com/Podcast: https://drmowll.com/podcastnew/ Book: ProFast Diet BookSTAY IN TOUCH WITH ME:You can find me on Instagram @daniellehamiltonhealth & on Facebook at Danielle Hamilton Health. My website is daniellehamiltonhealth.com (scroll down to sign up for my Newsletter!)Thank you for subscribing, rating, reviewing, sharing and reposting the show! I appreciate each and every one of you! ⭐️⭐️⭐️⭐️⭐️ 

MedEvidence! Truth Behind the Data
Fatty Liver & NASH in Clinical Trials

MedEvidence! Truth Behind the Data

Play Episode Play 23 sec Highlight Listen Later Jul 27, 2022 30:32 Transcription Available


This month's MedEvidence! Hour is a three-part series on You Cannot Live without Your LIVEr.   In this final 30-minute episode Doctors, Michael Koren and Bharat Misra dive into new treatments in clinical trials for Fatty Liver Disease and NASH.You will learnWhat is NASHWhat are the stages of NASHHow to treat NASHHow to find a clinical trialDr. Michael Koren, is a practicing cardiologist and CEO at ENCORE Research Group. He has been the principal investigator of 2000+ clinical trials while being published in the most prestigious medical journals. Dr. Koren received his medical degree cum laude at Harvard Medical School and completed his residency in internal medicine with a fellowship in cardiology at New York Hospital / Memorial Sloan-Kettering Cancer Center/ Cornell Medical Center.Dr. Bharat Misra is the Medical Director of ENCORE Borland Groover Clinical Research and has been a Principal Investigator of numerous clinical trials. He also serves on the Board of Directors at Memorial Hospital and Jacksonville Center for Clinical Research in Jacksonville, Florida. He completed his residency in internal medicine and fellowship in Gastroenterology at the Nassau University Medical Center, State University of New York, and his Bachelor of Medicine and Bachelor of Surgery from Gandhi Medical College in India.Rate, Review and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow MedEvidence! on Social Media to discover the Truth Behind the Data.FacebookInstagramTwitterLinkedInPowered by ENCORE Research Group at www.ENCOREDOCS.comOriginal Air Date: June 20, 2022

The Dr. Livingood Podcast - Make Health Simple
1 out of 2 Adults Have a Fatty Liver, Do You? 14 Day Liver Fix

The Dr. Livingood Podcast - Make Health Simple

Play Episode Listen Later Jul 24, 2022 8:02


One in two adults have a fatty liver and don't even know it! The good news is that there IS something you can do about it. Watch this video to find out how to fix your fatty liver in just 14 days! Get my Liver Detox here: https://store.drlivingood.com/products/livingood-daily-detox This episode was extracted from Dr. Livingood's YouTube channel. Click here to subscribe: https://bit.ly/3xUx8kl Or, click here to view the original video and any links referenced in this podcast: https://www.youtube.com/watch?v=m38bkkLOvjI

Dr. Berg’s Healthy Keto and Intermittent Fasting Podcast
The BEST Vitamin to Cleanse a Fatty Liver - Dr. Berg

Dr. Berg’s Healthy Keto and Intermittent Fasting Podcast

Play Episode Listen Later Jul 24, 2022 4:53


A fatty liver can be caused by many different things—not just alcohol. Check out the best vitamin to cleanse a fatty liver. Reduce Your Liver Fat by 50% in 14 Days: https://bit.ly/3aQzms2 DATA: https://bit.ly/3v35a3v https://bit.ly/3OgZbz7 https://bit.ly/3RKzrho Dr. Berg's Keto and IF Lab: https://www.facebook.com/groups/drbergslab/ How to Bulletproof your Immune System FREE Course: https://bit.ly/39Ry3s2 FREE MINI-COURSE ➜ ➜ Take Dr. Berg's Free Keto Mini-Course! ADD YOUR SUCCESS STORY HERE: https://bit.ly/3z9TviS Find Your Body Type: https://www.drberg.com/body-type-quiz Talk to a Product Advisor to find the best product for you! Call 1-540-299-1557 with your questions about Dr. Berg's products. Product Advisors are available Monday through Friday 8 am - 6 pm and Saturday 9 am - 5 pm EST. At this time, we no longer offer Keto Consulting and our Product Advisors will only be advising on which product is best for you and advise on how to take them. Dr. Eric Berg DC Bio: Dr. Berg, 51 years of age is a chiropractor who specializes in weight loss through nutritional & natural methods. His private practice is located in Alexandria, Virginia. His clients include senior officials in the U.S. government & the Justice Department, ambassadors, medical doctors, high-level executives of prominent corporations, scientists, engineers, professors, and other clients from all walks of life. He is the author of The 7 Principles of Fat Burning. Dr. Berg's Website: http://bit.ly/37AV0fk Dr. Berg's Recipe Ideas: http://bit.ly/37FF6QR Dr. Berg's Reviews: http://bit.ly/3hkIvbb Dr. Berg's Shop: http://bit.ly/3mJcLxg Dr. Berg's Bio: http://bit.ly/3as2cfE Dr. Berg's Health Coach Training: http://bit.ly/3as2p2q Facebook: https://www.facebook.com/drericberg Messenger: https://www.messenger.com/t/drericberg Instagram: https://www.instagram.com/drericberg/ YouTube: http://bit.ly/37DXt8C Pinterest: https://www.pinterest.com/drericberg/

One Funny Morning...with Dena Blizzard
One Funny Morning May 25th- Fatty Liver

One Funny Morning...with Dena Blizzard

Play Episode Listen Later Jul 21, 2022 35:56


MedEvidence! Truth Behind the Data
Common Fibroscan Technology Questions

MedEvidence! Truth Behind the Data

Play Episode Listen Later Jul 20, 2022 13:44 Transcription Available


This month's MedEvidence! Hour is a three-part series on You Cannot Live without Your LIVEr.   In this 14-minute Part 2 episode Doctors, Michael Koren and Bharat Misra answer your questions on Fibroscans.Who should receive a FibroscanHow often should I get a FibroscanShould I ask my primary doctor for a FibroscanLiver Biopsy vs. FibroscanInsurance and FibroscanWhat should I do after my FibroscanHow to find a free FibroscanDr. Michael Koren, is a practicing cardiologist and CEO at ENCORE Research Group. He has been the principal investigator of 2000+ clinical trials while being published in the most prestigious medical journals. Dr. Koren received his medical degree cum laude at Harvard Medical School and completed his residency in internal medicine with a fellowship in cardiology at New York Hospital / Memorial Sloan-Kettering Cancer Center/ Cornell Medical Center.Dr. Bharat Misra is the Medical Director of ENCORE Borland Groover Clinical Research and has been a Principal Investigator of numerous clinical trials. He also serves on the Board of Directors at Memorial Hospital and Jacksonville Center for Clinical Research in Jacksonville, Florida. He completed his residency in internal medicine and fellowship in Gastroenterology at the Nassau University Medical Center, State University of New York, and his Bachelor of Medicine and Bachelor of Surgery from Gandhi Medical College in India.Rate, Review and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow MedEvidence! on Social Media to discover the Truth Behind the Data.FacebookInstagramTwitterLinkedInPowered by ENCORE Research Group at www.ENCOREDOCS.comOriginal Air Date: June 20, 2022

Surfing the Nash Tsunami
S3-E36.5 - REGENERATE Redux: Clearing The Finish Line?

Surfing the Nash Tsunami

Play Episode Listen Later Jul 17, 2022 13:38


On July 7, Intercept Pharmaceuticals released new results from the continuation of the REGENERATE trial and announced their intent to file a new NDA for obeticholic acid (OCA) in NASH fibrosis. In this conversation, Stephen Harrison leads Jörn Schattenberg, Louise Campbell and Roger Green in considering whether the evidence in the new release will be sufficient to get the drug approved.Stephen starts by noting that we have not heard anything about the results of the REVERSE trial, which evaluated obeticholic acid (OCA) in patients with compensated cirrhosis. As he notes, even if OCA is not approved for cirrhosis, many hepatologists will consider giving this drug to cirrhotic patients, particularly compensated cirrhotics who face a significant worsening of their condition in a fairly short period of time. Jörn comments on this briefly to agree that the cirrhosis data will create a complete data set, then returns to the pruritus issue. Mostly, his point about cirrhosis is that given the high placebo rate suggests there is "something about how the question is asked." He finishes this comment by discussing the importance of getting a first drug approved and stating his anticipation of what happens when FDA reviews these data. Roger goes on to note that he has a unique experience in this group: he has discontinued a drug therapy based on pruritus (in his case, a cancer drug). Having lived through that experience, he expresses skepticism that pruritus that resolves on discontinuation will be a reason for the drug to be rejected. Stephen concurs, and Roger goes on to state that the perceived cardiovascular risk in 2020 made sense as a reason not to approve, but not pruritus. Stephen and Louise concur that we will not know the entire story until we know the lengths to which providers went to keep patients in this study, but both are hopeful (and pretty much expect) that while there may be boundaries on patient types and guidance on treatment, the case for approval appears likely to succeed. During the second half of this conversation, panelists share their common hope that this data will be sufficient to get OCA approved and discuss what this could mean for the entire Fatty Liver stakeholder community.

Dr. Berg’s Healthy Keto and Intermittent Fasting Podcast
Eat Liver and Egg Yolks to Prevent a Fatty Liver

Dr. Berg’s Healthy Keto and Intermittent Fasting Podcast

Play Episode Listen Later Jul 16, 2022 3:55


In this podcast, Dr. Berg explains how eating a grass-fed liver and egg yolks help improve fatty liver. US Wellness Meats: https://grasslandbeef.com/ DATA: http://bit.ly/2MTnrcu http://bit.ly/2tagTNr http://bit.ly/2GvU1Qg Dr. Berg's Keto and IF Lab: https://www.facebook.com/groups/drbergslab/ How to Bulletproof your Immune System FREE Course: https://bit.ly/39Ry3s2 FREE MINI-COURSE ➜ ➜ Take Dr. Berg's Free Keto Mini-Course! ADD YOUR SUCCESS STORY HERE: https://bit.ly/3z9TviS Find Your Body Type: https://www.drberg.com/body-type-quiz Talk to a Product Advisor to find the best product for you! Call 1-540-299-1557 with your questions about Dr. Berg's products. Product Advisors are available Monday through Friday 8 am - 6 pm and Saturday 9 am - 5 pm EST. At this time, we no longer offer Keto Consulting and our Product Advisors will only be advising on which product is best for you and advise on how to take them. Dr. Eric Berg DC Bio: Dr. Berg, 51 years of age is a chiropractor who specializes in weight loss through nutritional & natural methods. His private practice is located in Alexandria, Virginia. His clients include senior officials in the U.S. government & the Justice Department, ambassadors, medical doctors, high-level executives of prominent corporations, scientists, engineers, professors, and other clients from all walks of life. He is the author of The 7 Principles of Fat Burning. Dr. Berg's Website: http://bit.ly/37AV0fk Dr. Berg's Recipe Ideas: http://bit.ly/37FF6QR Dr. Berg's Reviews: http://bit.ly/3hkIvbb Dr. Berg's Shop: http://bit.ly/3mJcLxg Dr. Berg's Bio: http://bit.ly/3as2cfE Dr. Berg's Health Coach Training: http://bit.ly/3as2p2q Facebook: https://www.facebook.com/drericberg Messenger: https://www.messenger.com/t/drericberg Instagram: https://www.instagram.com/drericberg/ YouTube: http://bit.ly/37DXt8C Pinterest: https://www.pinterest.com/drericberg/

Surfing the Nash Tsunami
S3-E36 - REGENERATE Redux - Can OCA Succeed With New Data?

Surfing the Nash Tsunami

Play Episode Listen Later Jul 14, 2022 57:52


On July 7, Intercept Pharmaceuticals released new results from the continuation of the REGENERATE trial and announced their intent to file a new NDA for obeticholic acid (OCA) in NASH fibrosis. In this episode, Stephen Harrison leads the Surfers through a discussion of the new REGENERATE results and the Surfers discuss what they find compelling in the new data, discuss the possibility of approval, and ask (and answer) what an approval might mean for the Fatty Liver community.The basic structure of this episode is: Stephen Harrison walks the group through issues, opportunities and considerations raised in the July 7 press release and the rest of the panel responds with comments and questions as appropriate. He starts by noting that in a recent episode, the Surfers identified the release of updated REGENERATE data and subsequent OCA approval in NASH fibrosis as a potentially transformational event in the Fatty Liver community and proceeds to read the four bullet points that Intercept Pharmaceuticals highlighted:1.  The 25mg dose of OCA met the agreed primary endpoint of improvement in liver fibrosis without worsening of NASH at 18 months. 2.  The 25mg dose of OCA  doubled the fibrosis response rate vs. placebo.3.  This data set includes larger and more robust safety database of 2477 patients with nearly 1000 on study drug for four years. 4.  Intercept will refile an NDA in liver fibrosis due to NASH, starting with a pre-submission meeting with the FDA later this month. From there, Stephen dives into the data, starting with the efficacy results. He notes that the results for reduction of fibrosis without worsening of NASH are comparable to the initial REGENERATE results statistically: highly significant improvement in the 25mg dose vs. placebo, but not in the 10 mg dose. He also notes a small but statistically insignificant numerical difference in NASH resolution without worsening of fibrosis. The 25mg score is roughly the same as in the earlier trial, but the placebo score dropped, possibly due to a change in the methodology for reading histology slides .  In the previous analysis, two histopathologists each read half the slides independently. This time, two teams of three histopathologists read slides in a design that forced consensus on each slide included in the final data. In discussing efficacy data, Jörn describes this study as "groundbreaking" and Louise notes the impact of a two-years-later approval in terms of patients who did not receive drug benefit over that time.  In agreeing with Jörn, Stephen notes that this study proves that we can get a fibrosis drug "over the finish line" by meeting FDA efficacy criteria.The group moves on to discuss safety criteria. Stephen notes that pruritus is still the most common side effect and reason for discontinuation, while Roger comments that LDL and cardiovascular issues, which were implicated as the major risk issue in the earlier data, appear to resolve over time and not present as much risk this time. Jörn and Louise both praise the increased robustness of safety data based on sample size and duration of therapy, after which Stephen notes the questions that the press release does not answer (but, presumably, the full data release will).  The rest of the discussion focuses on some decisions Intercept made about how to present data and the overall implications of this trial. Stephen and Roger praise Intercept for their continued commitment to OCA in the face of FDA's 2019 Complete Response Letter and the group agrees that this data is more likely to gain approval. When Roger asks for a prediction of what the world might look like 1-2 years from now, the group considers that we might have two approved agents (with resmetirom) as early as the end of 2023.

MedEvidence! Truth Behind the Data
You Cannot Live without Your LIVEr

MedEvidence! Truth Behind the Data

Play Episode Listen Later Jul 13, 2022 12:21 Transcription Available


This month's MedEvidence! Hour is a three-part series on You Cannot Live without Your LIVEr.   In this 12-minute Part 1 episode Doctors, Michael Koren and Bharat Misra discuss technologies to diagnose dysfunctions of the liver.You will learn:Technologies in Clinical ResearchWhat is a FibroscanWhy your doctor may not be offering you a FibroscanLiver Biopsy vs. MRI vs. FibroscanDr. Michael Koren, is a practicing cardiologist and CEO at ENCORE Research Group. He has been the principal investigator of 2000+ clinical trials while being published in the most prestigious medical journals. Dr. Koren received his medical degree cum laude at Harvard Medical School and completed his residency in internal medicine with a fellowship in cardiology at New York Hospital / Memorial Sloan-Kettering Cancer Center/ Cornell Medical Center.Dr. Bharat Misra is the Medical Director of ENCORE Borland Groover Clinical Research and has been a Principal Investigator of numerous clinical trials. He also serves on the Board of Directors at Memorial Hospital and Jacksonville Center for Clinical Research in Jacksonville, Florida. He completed his residency in internal medicine and fellowship in Gastroenterology at the Nassau University Medical Center, State University of New York, and his Bachelor of Medicine and Bachelor of Surgery from Gandhi Medical College in India.Rate, Review and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow MedEvidence! on Social Media to discover the Truth Behind the Data.FacebookInstagramTwitterLinkedInPowered by ENCORE Research Group at www.ENCOREDOCS.comOriginal Air Date: June 20, 2022

Dishing Up Nutrition
Fatty Liver & The Food Connection

Dishing Up Nutrition

Play Episode Listen Later Jul 10, 2022 42:15 Very Popular


Today we will share the reasons why almost two billion people worldwide have a condition known as fatty liver disease. We'll talk about the two main types of fatty liver disease, discuss how what you eat and drink affects your liver, cover the health problems related to fatty liver disease, and, most importantly, share how you can reverse a fatty liver with a real food plan.

FUNC YOU UP!
Ep 143: Reversing Fatty Liver

FUNC YOU UP!

Play Episode Listen Later Jun 30, 2022 21:35


So the bad news is that fatty liver is extremely common (affecting 1 in 2 Americans), but the good news is that it's completely reversible! Let's talk about how through diet and lifestyle changes, your liver can thrive. How fat is not the enemy and can actually aid in healing fatty liver, and a very long list of foods, supplements and herbs. So grab a pen and paper. Can't get enough FUNC YOU UP!? Follow @michellemiller_msacn, @kbova_nutrition, and @physiologicnyc for more functional nutrition and health. In the meantime, leave us a review on iTunes, follow us on Spotify and share! FUNC YOU UP! is a Physio Logic wellness podcast covering the best in wellness, nutrition, and functional medicine in twenty minutes or less with hosts Michelle Miller, Functional Nutritionist, and Kendra Bova, Functional Medicine Registered Dietitian. https://physiologicnyc.com/func-you-up-podcast #IntegrativeNutrition #FunctionalMedicine #FattyLiver

America's Heroes Group
Ep. 315 - PSA warning Fatty Liver is affecting Young Adults and Women Veterans

America's Heroes Group

Play Episode Listen Later Jun 20, 2022 24:26


America's Heroes Group Roundtable with Partner National Nurses UnitedPartner: Adelena Marshall - VA Mental Health RN

The Melanie Avalon Biohacking Podcast
#149 - Chris Masterjohn: Achieving Ideal Nutritional Status, Dietary Recommendations & Requirements, How Omega-6s Resolve Inflammation, Vitamin Supplementation & Limits, Veganism Implications, Choline & Fatty Liver, Aspirin Benefits, And More!

The Melanie Avalon Biohacking Podcast

Play Episode Listen Later Jun 10, 2022 127:07 Transcription Available Very Popular


GET TRANSCRIPT AND FULL SHOWNOTES: melanieavalon.com/chrismasterjohn 2:25 - IF Biohackers: Intermittent Fasting + Real Foods + Life: Join Melanie's Facebook Group At Facebook.com/groups/paleoOMAD For A Weekly Episode GIVEAWAY, And To Discuss And Learn About All Things Biohacking! All Conversations Welcome! 2:40 - Follow Melanie On Instagram To See The Latest Moments, Products, And #AllTheThings! @MelanieAvalon 3:10 - AVALONX SERRAPEPTASE: Get Melanie's Serrapeptase Supplement: A Proteolytic Enzyme Which May Help Clear Sinuses And Brain Fog, Reduce Allergies, Support A Healthy Inflammatory State, Enhance Wound Healing, Break Down Fatty Deposits And Amyloid Plaque, Supercharge Your Fast, And More!  AvalonX Supplements Are Free Of Toxic Fillers And Common Allergens (Including Wheat, Rice, Gluten, Dairy, Shellfish, Nuts, Soy, Eggs, And Yeast), Tested To Be Free Of Heavy Metals And Mold, And Triple Tested For Purity And Potency. Order At avalonx.us, And Get On The Email List To Stay Up To Date With All The Special Offers And News About Melanie's New Supplements At avalonx.us/emaillist, And Use The Code MelanieAvalon For 10% On Any Order At avalonx.us And mdlogichealth.com!  6:40 - FOOD SENSE GUIDE: Get Melanie's App At Melanieavalon.com/foodsenseguide To Tackle Your Food Sensitivities! Food Sense Includes A Searchable Catalogue Of 300+ Foods, Revealing Their Gluten, FODMAP, Lectin, Histamine, Amine, Glutamate, Oxalate, Salicylate, Sulfite, And Thiol Status. Food Sense Also Includes Compound Overviews, Reactions To Look For, Lists Of Foods High And Low In Them, The Ability To Create Your Own Personal Lists, And More! 7:15 - BEAUTYCOUNTER: Non-Toxic Beauty Products Tested For Heavy Metals, Which Support Skin Health And Look Amazing! Shop At beautycounter.com/melanieavalon For Something Magical! For Exclusive Offers And Discounts, And More On The Science Of Skincare, Get On Melanie's Private Beautycounter Email List At melanieavalon.com/cleanbeauty! Find Your Perfect Beautycounter Products With Melanie's Quiz: melanieavalon.com/beautycounterquiz 12:30 - Chris' Start In Nutrition 17:20 - Weston Price's Principals 26:25 - LMNT: For Fasting Or Low-Carb Diets Electrolytes Are Key For Relieving Hunger, Cramps, Headaches, Tiredness, And Dizziness. With No Sugar, Artificial Ingredients, Coloring, And Only 2 Grams Of Carbs Per Packet, Try LMNT For Complete And Total Hydration. For A Limited Time Go To drinklmnt.com/melanieavalon To Get A Sample Pack For Only The Price Of Shipping! 30:15 - Veganism 32:30 - Longevity With Veganism 37:00 - Creatine 39:20 - Synthesizing Vitamins, Deficiencies, And RDAs 47:20 - Niacin 52:50 - Cravings Driving Food Intake 56:00 - Supplement Toxicity 1:03:30 - Liver As A Superfood 1:07:30 - A Study Rats Unnatural Diet & Environment 1:14:15 - DRY FARM WINES: Low Sugar, Low Alcohol, Toxin-Free, Mold-Free, Pesticide-Free, Hang-Over Free Natural Wine! Use The Link dryfarmwines.com/melanieavalon To Get A Bottle For A Penny! 1:17:00 - The Derangement Of The Modern Palate 1:22:20 - Choline & Fatty Liver 1:32:00 - Is Choline Production Demand Driven? 1:32:45 - High Dose Choline 1:34:40 - Polyunsaturated Fats, EPA, DHA & Inflammation 1:44:00 - The Balance Of Different Cell Types & Wound Healing 1:52:30 - Resolution Of Healing 1:54:45 - Omega-3s 1:56:55 - Aspirin 1:59:10 - NR Vs NMN

Dr. Berg’s Healthy Keto and Intermittent Fasting Podcast
How to Prevent Fatty Liver When You Lose Weight – Dr. Berg

Dr. Berg’s Healthy Keto and Intermittent Fasting Podcast

Play Episode Listen Later Jun 7, 2022 4:01


Did you know that losing weight could contribute to a fatty liver? Here's how to prevent fatty liver when you lose weight. FREE COURSE ➜ ➜ https://courses.drberg.com/product/how-to-bulletproof-your-immune-system/ FREE MINI-COURSE ➜ ➜ Take Dr. Berg's Free Keto Mini-Course! ADD YOUR SUCCESS STORY HERE: https://bit.ly/3z9TviS Find Your Body Type: https://www.drberg.com/body-type-quiz Talk to a Product Advisor to find the best product for you! Call 1-540-299-1557 with your questions about Dr. Berg's products. Product Advisors are available Monday through Friday 8 am - 6 pm and Saturday 9 am - 5 pm EST. At this time, we no longer offer Keto Consulting and our Product Advisors will only be advising on which product is best for you and advise on how to take them. Dr. Eric Berg DC Bio: Dr. Berg, 51 years of age is a chiropractor who specializes in weight loss through nutritional & natural methods. His private practice is located in Alexandria, Virginia. His clients include senior officials in the U.S. government & the Justice Department, ambassadors, medical doctors, high-level executives of prominent corporations, scientists, engineers, professors, and other clients from all walks of life. He is the author of The 7 Principles of Fat Burning. Dr. Berg's Website: http://bit.ly/37AV0fk Dr. Berg's Recipe Ideas: http://bit.ly/37FF6QR Dr. Berg's Reviews: http://bit.ly/3hkIvbb Dr. Berg's Shop: http://bit.ly/3mJcLxg Dr. Berg's Bio: http://bit.ly/3as2cfE Dr. Berg's Health Coach Training: http://bit.ly/3as2p2q Facebook: https://www.facebook.com/drericberg Messenger: https://www.messenger.com/t/drericberg Instagram: https://www.instagram.com/drericberg/ YouTube: http://bit.ly/37DXt8C Pinterest: https://www.pinterest.com/drericberg/

Dr. Berg’s Healthy Keto and Intermittent Fasting Podcast
Best Liver Cleansing Shake for a Fatty Liver!

Dr. Berg’s Healthy Keto and Intermittent Fasting Podcast

Play Episode Listen Later May 12, 2022 3:47


Dr. Berg makes a shake out of kale, parsley, beet tops and a small amount of fruit. This combination can flush fluid out of the body and is great for ridding fat from the liver. FREE COURSE ➜ ➜ https://courses.drberg.com/product/how-to-bulletproof-your-immune-system/ FREE MINI-COURSE ➜ ➜ Take Dr. Berg's Free Keto Mini-Course! ADD YOUR SUCCESS STORY HERE: https://bit.ly/3z9TviS Find Your Body Type: https://www.drberg.com/body-type-quiz Talk to a Product Advisor to find the best product for you! Call 1-540-299-1557 with your questions about Dr. Berg's products. Product Advisors are available Monday through Friday 8 am - 6 pm and Saturday 9 am - 5 pm EST. At this time, we no longer offer Keto Consulting and our Product Advisors will only be advising on which product is best for you and advise on how to take them. Dr. Eric Berg DC Bio: Dr. Berg, 51 years of age is a chiropractor who specializes in weight loss through nutritional & natural methods. His private practice is located in Alexandria, Virginia. His clients include senior officials in the U.S. government & the Justice Department, ambassadors, medical doctors, high-level executives of prominent corporations, scientists, engineers, professors, and other clients from all walks of life. He is the author of The 7 Principles of Fat Burning. Dr. Berg's Website: http://bit.ly/37AV0fk Dr. Berg's Recipe Ideas: http://bit.ly/37FF6QR Dr. Berg's Reviews: http://bit.ly/3hkIvbb Dr. Berg's Shop: http://bit.ly/3mJcLxg Dr. Berg's Bio: http://bit.ly/3as2cfE Dr. Berg's Health Coach Training: http://bit.ly/3as2p2q Facebook: https://www.facebook.com/drericberg Messenger: https://www.messenger.com/t/drericberg Instagram: https://www.instagram.com/drericberg/ YouTube: http://bit.ly/37DXt8C Pinterest: https://www.pinterest.com/drericberg/

The Cabral Concept
2283: Burning Mouth Syndrome, Non-Alcoholic Fatty Liver, Sebaceous Filaments, Antibiotic Story, CBD & Pregnancy , Fasting & Belly Fat (HouseCall)

The Cabral Concept

Play Episode Listen Later May 7, 2022 17:47


Welcome back to our weekend Cabral HouseCall shows! This is where we answer our community's wellness, weight loss, and anti-aging questions to help people get back on track!   Check out today's questions:    Shirleyta: I have suffered for BMS for 1.5 years.. what should I do, Doctor? What kind of specific Doctor do I need . Thank you for your kind attention.   Fiona: Scans show fatty liver but I don't consume any alcohol, my diet is organic and plant-based with no processed foods. How is this possible?   Anonymous: Hi there! Firstly, thank you for all the knowledge and wisdom you share! I have been working on healing my gut for about 3 months now. I have noticed some changes like more energy, less cravings, better sleep. However, I am still really struggling with my skin. My skin periodically gets this sort of rash that looks like sebaceous filaments and water retention. I know sebaceous filaments are natural but they are not always this prominent. Are there foods that cause this? Also, I have noticed that i have a sensitivity to lectins and a lot of the protein sources on the Dr. Cabral detox are a bit high in lectins(beans, legumes, chia seeds). I listened to your podcast on eliminating them for a while if one is sensitive and then reintroducing them later on. How can I modify the detox so that I still get enough protein while also avoiding lectins? Thank you so much in advance!   Moriah: I was just listening to your podcast and you said something word for word what I said to myself a year ago… “I won't take antibiotics unless I'm dying” Last year, antibiotics caused me to catch a c diff infection and I've never been so sick, the antibiotics they gave me to cure the c diff, didn't even work and I got a second infection, I literally felt like I could have died. A local naturopath finally helped me heal my gut and repair my issues. Just wanted to say thank you for speaking out about the danger of unnecessary use of antibiotics   Lisa: Is it ok to use cbd oil while pregnant? I have been using cbd oil for 2-3 years to help me sleep at night and I can't sleep well without it. Thoughts on taking it during pregnancy ?   Anonymous: Hi. I have been listening to your podcast for a while and it has really been helping a lot with my health issues. In numerous podcast episodes, you have mentioned that keto and long intermittent fasting isn't good for female hormones. I have extreme insulin resistance and I have had it for years. I have tried keto with vegetables for about 3 weeks now along with intermittent fasting of 16 hours in order to try to reduce my insulin resistance, hair loss at temples, and skin rash. However, i seem to be gaining more weight around the belly even though I have not been consuming any carbs other than low glycemic vegetables. What could be causing this? I thought that belly fat especially love handles were caused by high insulin? Also, what method would you suggest for healing extreme insulin resistance for a female? Thank you so much in advance!    Thank you for tuning into today's Cabral HouseCall and be sure to check back tomorrow where we answer more of our community's questions!    - - - Show Notes & Resources: http://StephenCabral.com/2283 - - - Get Your Question Answered: http://StephenCabral.com/askcabral   - - - Dr. Cabral's New Book, The Rain Barrel Effect https://amzn.to/2H0W7Ge - - - Join the Community & Get Your Questions Answered: http://CabralSupportGroup.com - - -  Dr. Cabral's Most Popular At-Home Lab Tests: > Complete Minerals & Metals Test (Test for mineral imbalances & heavy metal toxicity) - - - > Complete Candida, Metabolic & Vitamins Test (Test for 75 biomarkers including yeast & bacterial gut overgrowth, as well as vitamin levels) - - - > Complete Stress, Mood & Metabolism Test (Discover your complete thyroid, adrenal, hormone, vitamin D & insulin levels) - - - > Complete Stress, Sleep & Hormones Test (Run your adrenal & hormone levels) - - - > Complete Food Sensitivity Test (Find out your hidden food sensitivities) - - - > Complete Omega-3 & Inflammation Test (Discover your levels of inflammation related to your omega-6 to omega-3 levels) - - - > View all Functional Medicine lab tests (View all Functional Medicine lab tests you can do right at home for you and your family)